Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
Immunome (IMNM) Stock Price & Analysis
148 Followers
IMNM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.44 - $30.96
Previous Close$13.73
Volume967.62K
Average Volume (3M)803.34K
Market Cap
$875.12M
Enterprise Value$681.46M
Total Cash (Recent Filing)$138.14M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-2.5
Beta1.21
Next Earnings
May 09, 2024EPS Estimate
-$0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.38
Shares Outstanding59,694,243
10 Day Avg. Volume998,283
30 Day Avg. Volume803,338
Standard Deviation0.44
R-Squared0.04
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)7.10
Price to Sales (P/S)58.47
Price to Cash Flow (P/CF)-12.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue48.61
Enterprise Value/Gross Profit48.61
Enterprise Value/Ebitda11.99
Forecast
1Y Price Target
$35.33Price Target Upside157.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Immunome News
PremiumCompany Announcements
Immunome Appoints Sandra Swain and Revises Audit Committee
PremiumCompany Announcements
Immunome’s Strategic Acquisition to Revolutionize Cancer Treatment
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe anticipated results from the Phase 3 RINGSIDE trial could mark a significant advancement for the company into late-stage clinical development.
Financial HealthWith a robust cash position enhanced by recent financing, the company is well-capitalized to support its ongoing research and development efforts.
Product DifferentiationAL-102's high overall response rate in Phase 2 trials suggests a strong potential to stand out from competitors, offering a new hope for treatment efficacy.
Bears Say
Analyst Price TargetThe price target for IMNM has been lowered to $38 from $40, primarily due to the share dilution.
Clinical Trial ResultsTopline data from the RINGSIDE trial is anticipated to be available in late 2025.
Financial CommitmentsIMNM is responsible for up to $142mn in clinical development and regulatory milestones, as well as up to $50mn for commercial milestones, which signifies financial commitments that could impact cash flow.
---
Ownership Overview
5.36% Insiders
9.85% Mutual Funds
4.56% Other Institutional Investors
80.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $4.44 and its highest was $30.96 in the past 12 months.
What is Immunome’s market cap?
Currently, no data Available
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is May 09, 2024 which is in 11 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Mar 28, 2024. The company reported -$4.21 earnings per share for the quarter, missing the consensus estimate of -$0.273 by -$3.937.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -$0.79.
How many shares outstanding does Immunome have?
Immunome has 59,694,244 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$4.21 in its last earnings report, missing expectations of -$0.273. Following the earnings report the stock price went down -10.413%.
Which hedge fund is a major shareholder of Immunome?
Among the largest hedge funds holding Immunome’s share is Woodline Partners LP. It holds Immunome’s shares valued at 10M.
---
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.33 (157.32% Upside)
$35.33 (157.32% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 14.7%
Last 30 Days ▼ 14.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
159.05%
12-Months-Change
Fundamentals
Return on Equity
-156.45%
Trailing 12-Months
Asset Growth
517.73%
Trailing 12-Months
Company Description
Immunome
Immunome Inc is a biopharmaceutical company engaged in the discovery and development of novel antibody-based drugs. The company's proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. It is developing treatments for treating cancer and other infectious diseases.
---
IMNM Stock 12 Months Forecast
Average Price Target
$35.33
▲(157.32% Upside)
Technical Analysis
Best Analysts Covering IMNM
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+144.10%
reiterated a buy rating 10 months ago
Copying Matthew Barcus's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +144.10% per trade.
---